161 related articles for article (PubMed ID: 33641655)
1. 20(
Liang Y; Zhang T; Jing S; Zuo P; Li T; Wang Y; Xing S; Zhang J; Wei Z
Am J Chin Med; 2021; 49(3):753-765. PubMed ID: 33641655
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.
Li Y; Wang Y; Niu K; Chen X; Xia L; Lu D; Kong R; Chen Z; Duan Y; Sun J
Oncotarget; 2016 Oct; 7(43):70535-70545. PubMed ID: 27655708
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1
Li X; Tsauo J; Geng C; Zhao H; Lei X; Li X
Am J Chin Med; 2018; 46(8):1915-1931. PubMed ID: 30525897
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Proteomics Combined with Affinity MS Revealed the Molecular Mechanism of Ginsenoside Antitumor Effects.
Wang Z; Kim U; Jiao Y; Li C; Guo Y; Ma X; Jiang M; Jiang Z; Hou Y; Bai G
J Proteome Res; 2019 May; 18(5):2100-2108. PubMed ID: 30860844
[TBL] [Abstract][Full Text] [Related]
5. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
[TBL] [Abstract][Full Text] [Related]
6. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
7. Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor.
Joo EJ; Chun J; Ha YW; Ko HJ; Xu MY; Kim YS
Chem Biol Interact; 2015 May; 233():25-34. PubMed ID: 25824408
[TBL] [Abstract][Full Text] [Related]
8. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Wang XJ; Zhou RJ; Zhang N; Jing Z
Eur J Pharmacol; 2019 May; 850():141-149. PubMed ID: 30772396
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway.
Liu T; Zuo L; Guo D; Chai X; Xu J; Cui Z; Wang Z; Hou C
Biomed Pharmacother; 2019 Dec; 120():109483. PubMed ID: 31629252
[TBL] [Abstract][Full Text] [Related]
10. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
11. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
12. Ginsenosides Inhibit the Proliferation of Lung Cancer Cells and Suppress the Rate of Metastasis by Modulating EGFR/VEGF Signaling Pathways.
Yu X; Wang Q; Dai Z
J Oleo Sci; 2024; 73(2):219-230. PubMed ID: 38311411
[TBL] [Abstract][Full Text] [Related]
13. 20(S)-Protopanaxadiol blocks cell cycle progression by targeting epidermal growth factor receptor.
Zhang T; Liang Y; Zuo P; Jing S; Li T; Wang Y; Lv C; Li D; Zhang J; Wei Z
Food Chem Toxicol; 2020 Jan; 135():111017. PubMed ID: 31805304
[TBL] [Abstract][Full Text] [Related]
14. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
15. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
16. EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
Lin C; Qin Y; Zhang H; Gao MY; Wang YF
Oncol Rep; 2018 Jul; 40(1):29-38. PubMed ID: 29749533
[TBL] [Abstract][Full Text] [Related]
17. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
[TBL] [Abstract][Full Text] [Related]
18. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
